Academic Journal
Q1ESMO Open
About ESMO Open
ESMO Open is a scholarly journal published by Elsevier B.V.. SCImago 2025 lists it in Q1, with an SJR of 3.455 and H-index of 81.
Coverage: 2016-2026. Research categories: Cancer Research (Q1); Oncology (Q1).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Cancer Immunotherapy and Biomarkers; Lung Cancer Treatments and Mutations; Advanced Breast Cancer Therapies; Breast Cancer Treatment Studies; HER2/EGFR in Cancer Research; Cancer Genomics and Diagnostics.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Atezolizumab plus pertuzumab, trastuzumab, and chemotherapy in HER2-positive early breast cancer: final results of the phase III IMpassion050 trial
J. Huober, C.H. Barrios, N. Niikura, M. Jarząb et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108541Tumor genomic landscape of older patients with metastatic breast cancer☆
H. Gupta, K.D. Brantley, T. Grinda, R.A. Freedman et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108540Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials
A. Cigliola, A. Larcher, B.A. Maiorano, D. Robesti et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108543Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma
R. Kanesvaran, V. Gruenwald, A. Wong, J. Chan et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108552Access to cancer clinical trials in Europe: when trial availability does not match patient need
A.D. Lázaro Sánchez, J.D. Benitez-Fuentes, L.-A. Teuwen, E. Baloyan et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108577Pseudoprogression in neoadjuvant immunotherapy for resectable NSCLC: a PET–CT-based study
Y. Pan, J. Chen, H. Lin, L.-B. Tang et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108368Zolbetuximab plus chemotherapy versus immune checkpoint inhibitor regimens by programmed death-ligand 1 combined positive score in locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: a Bayesian network meta-analysis
K. Shitara, S.Y. Rha, S.J. Klempner, F. Lordick et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108530Liquid biopsy: a new window on the BRCA genes
L. Incorvaia, V. Gristina, F. Pepe, T.D. Bazan Russo et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108349Clinically actionable genomic alterations in breast cancer brain metastases
G. Griguolo, A. Collesei, E. Lazzarini, M. Bottosso et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108551Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort
R. Garcia-Carbonero, G.M. Cote, A. Le Cesne, B. Antón-Pascual et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108534Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma
Y. Loriot, N. Matsubara, S.H. Park, R.A. Huddart et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108583Real-world treatment patterns and associated outcomes in patients with HER2-positive unresectable or metastatic breast cancer: the HER2 REAL Study
S.C. Lee, C. Barrios, W.-P. Chung, R.N. Kai Cheong et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108326Insights into rhabdomyosarcoma in the adolescent and young adult population: a comprehensive clinical study from the French Society of Pediatric Oncology (SFCE) Malignant Mesenchymal Tumor (MMT) Committee and the French Sarcoma Group (GSF-GETO)
C. Khanfar, F. Sevrin, E. Bogart, M. Karanian et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108539Association between symptom experience and long-term survival in people treated for cancer
K. Hofsø, T. Rustøen, K. Bjordal, M. Hagen et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108579Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gaps
Y. Iimura, R. Chow, D. Watanabe, T. Hayashi et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108582Advancing cancer care for adolescents and young adults: the role of the European Network of Expertise
A. Ferrari, S. Provenzano, C. Prampolini, W. van der Graaf et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108542Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting
G. Curigliano, M. De Laurentiis, N. Harbeck, S. Kuemmel et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108535Collecting duct carcinoma: new biological inroads in this rarest of rare cancers
R. Agarwal, G. Zhang, S.K. Pal
2026-10 · DOI: 10.1016/j.esmoop.2026.108531Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study
S.Y. Rha, L.S. Wyrwicz, P. Yañez, Y. Bai et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108536Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort
S. Wang, Q. Zhang, Z. Jiang, Z. Tong et al.
2026-10 · DOI: 10.1016/j.esmoop.2026.108538Reviews
Community Reviews
Version History
September 13, 2026 at 11:15 am
September 13, 2026